UBX-1325 is a small molecule commercialized by Unity Biotechnology, with a leading Phase II program in Diabetic Macular Edema. According to Globaldata, it is involved in 4 clinical trials, of which 1 was completed, 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of UBX-1325’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for UBX-1325 is expected to reach an annual total of $36 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
UBX-1325 Overview
UBX-1325 is under development for the treatment of ophthalmological diseases such as diabetic retinopathy, diabetic macular edema, choroidal neovascularization associated with age-related macular degeneration and neovascular age related macular degeneration. The drug candidate is a backup to UBX1967 that acts by targeting BCL2. It is administered through intravitreal route.
Unity Biotechnology Overview
Unity Biotechnology develops and commercializes therapies for the treatment of age-related diseases. The company focuses on the development of senolytic medicines to eliminate senescent cells. Unity Biotechnology’s product portfolio includes UBX0101, intended for musculoskeletal diseases; and UBX1325, for age-related diseases, including diabetic retinopathy and diabetic macular edema, glaucoma and age-related macular degeneration. It is also involved in developing products for idiopathic pulmonary fibrosis, systemic sclerosis, chronic obstructive pulmonary disease, cognition and kidney disease. The company works in collaboration with research institutions, academic, contract research organizations to develop its product portfolio. Unity Biotechnology is headquartered in Brisbane, California, the US.
The company reported revenues of (US Dollars) US$4.8 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$56.5 million in FY2021, compared to an operating loss of US$93.9 million in FY2020. The net loss of the company was US$60.7 million in FY2021, compared to a net loss of US$93.8 million in FY2020.
For a complete picture of UBX-1325’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
